Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Cash Flow (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Net Cash Flow data on record, last reported at -$4.3 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 93.25% year-over-year to -$4.3 million; the TTM value through Dec 2025 reached -$28.9 million, down 68.68%, while the annual FY2025 figure was -$28.9 million, 68.68% down from the prior year.
  • Net Cash Flow reached -$4.3 million in Q4 2025 per ARQT's latest filing, up from -$25.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $223.6 million in Q1 2021 and bottomed at -$199.6 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$1.2 million, with a median of -$6.3 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: crashed 931.49% in 2021, then soared 1975.78% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $44.7 million in 2021, then tumbled by 162.46% to -$27.9 million in 2022, then surged by 31.4% to -$19.1 million in 2023, then crashed by 230.61% to -$63.3 million in 2024, then soared by 93.25% to -$4.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$4.3 million in Q4 2025, -$25.5 million in Q3 2025, and $19.1 million in Q2 2025.